Stanford neuromodulation therapy for treatment‐resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy

Stanford neuromodulation therapy (SNT) is a rapid‐acting, high‐dose, intermittent theta‐burst stimulation protocol. Although it has previously demonstrated efficacy for treatment‐resistant depression (TRD) in a randomized controlled trial (RCT), replication in a larger sample is needed. Additionally, the electrophysiological effects of SNT remain unknown. Here we report results from a new double‐blind, sham‐controlled RCT along with electroencephalography (EEG) findings from the initial and current trials. In the current RCT, 53 participants with TRD were enrolled, and 48 who continued to meet entry criteria were randomized to receive active (N=24) or sham (N=24) SNT. At 1‐month, remission (primary outcome)…

• MF
  Mellam Family Foundation
• NI
  National Institute of Mental Health